TG THERAPEUTICS, INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $TGTX in the last 30 days.
See all $TGTX insider activity →iShares Trust (IJT) reported $148.6M net outflow on Oct. 26, selling $1.8M each of VSAT, PTGX, and RHP. IJT holds 345 stocks, with top sectors being Technology, Industrials, and Healthcare. The fund's top holdings include VSAT, PTGX, and RHP, each at around 1.11%. IJT has a P/E of 19.24, P/B of 3.01, and a YTD return of 16.42%.
TG Therapeutics (TGTX) shared initial Phase 1 data for azer-cel in 26 progressive MS patients, showing B-cell depletion and stable or improved disability in 18 evaluable patients, with five showing EDSS improvements. Follow-up is short, and dose escalation continues.
TG Therapeutics (TGTX) announced seven-year data for BRIUMVI, Phase 3 dosing results, and Phase 1 subcutaneous data. The company also shared real-world updates and initial Phase 1 results for azer-cel in PPMS. These updates may support BRIUMVI's lifecycle and early pipeline options in MS, but larger catalysts will require further peer-reviewed results or regulatory filings.
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning TGTX (TG THERAPEUTICS, INC.). Coverage has skewed bullish: 4 bullish, 0 neutral, and 1 bearish.
Recent TGTX coverage spans financial news, market movers and sector analysis.
The trim indicates reduced ETF exposure, which can modestly affect demand but is unlikely to dominate price action alone.
Early positive trial signals could lift sentiment and attract speculative buying, but the small sample and early stage limit immediate price impact.
The fresh clinical data could lift the stock as investors price in potential efficacy and future regulatory filings.
Positive long-term efficacy data likely supports upside for TG Therapeutics.
The comparative efficacy data may boost investor confidence in TG Therapeutics and its BRIUMVI product.
AlphAI scores every news story that mentions TGTX with an AI model for sentiment and relevance, and aggregates insider trades from TG THERAPEUTICS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
iShares Trust (IJT) reported $148.6M net outflow on Oct. 26, selling $1.8M each of VSAT, PTGX, and RHP. IJT holds 345 stocks, with top sectors being Technology, Industrials, and Healthcare. The fund's top holdings include VSAT, PTGX, and RHP, each at around 1.11%. IJT has a P/E of 19.24, P/B of 3.01, and a YTD return of 16.42%.
5 min readTG Therapeutics (TGTX) shared initial Phase 1 data for azer-cel in 26 progressive MS patients, showing B-cell depletion and stable or improved disability in 18 evaluable patients, with five showing EDSS improvements. Follow-up is short, and dose escalation continues.
1 min readTG Therapeutics (TGTX) announced seven-year data for BRIUMVI, Phase 3 dosing results, and Phase 1 subcutaneous data. The company also shared real-world updates and initial Phase 1 results for azer-cel in PPMS. These updates may support BRIUMVI's lifecycle and early pipeline options in MS, but larger catalysts will require further peer-reviewed results or regulatory filings.
2 min readTG Therapeutics presented data on BRIUMVI (ublituximab) at MSToronto2026, showing 88% of patients had no disability progression after 7 years. Phase 3 ENHANCE trial supports a single-dose initiation schedule. Phase 1 data supports quarterly subcutaneous dosing. Azer-cel Phase 1 data for PPMS will be presented October 23, 2026. Michael S. Weiss, CEO, highlighted the potential of BRIUMVI in relapsing MS.
2 min readTG Therapeutics' BRIUMVI showed lower 5-year disability progression (9.4%) vs. ofatumumab (17.9%) and ocrelizumab in a MAIC analysis, with 44% and 49% lower hazard ratios, respectively. CEO Michael S. Weiss highlighted the importance of these findings for MS treatment. The study was funded by Neuraxpharm, TG's European partner.
2 min readTG Therapeutics (TGTX) has seen a 7x return over three years, raising questions about its valuation. With a P/E of 17.1x, similar to the biotech industry average, analysts debate whether the stock is undervalued. Upcoming clinical data on BRIUMVI and azer cel could impact future profitability and investor willingness to pay. Community views split between bullish and bearish cases, with some seeing a 23% undervaluation and others a 85% overvaluation.
2 min readTG Therapeutics (TGTX) announced data presentations at MSToronto2026, including initial results from a Phase 1 study of azer-cel in progressive multiple sclerosis and multiple presentations on BRIUMVI (ublituximab-xiiy). The company highlighted seven-year clinical outcomes, real-world evidence, and Phase 3 ENHANCE data supporting a single-dose initiation schedule for BRIUMVI. Presentations will occur from October 21-23, 2026.
2 min readArgus lowered its target price for TG Therapeutics (TGTX) to $57.00. The company is a biopharmaceutical firm focused on treating B-cell diseases.
1 min readB. Riley analyst Mayank Mamtani highlighted top biotech picks ahead of 3Q26 earnings, including Axsome Therapeutics (AXSM), Cytokinetics (CYTK), Eton Pharmaceuticals (ETON), Harrow (HROW), TG Therapeutics (TGTX), and Zymeworks (ZYME). The analyst provided price targets and revenue projections for each, noting macroeconomic challenges for small and mid-cap biotech stocks.
3 min readInsiders at Guardant Health (GH), Geo Group (GEO), Tower Semiconductor (TSEM), TG Therapeutics (TGTX), and GigaCloud (GCT) sold shares. GH saw $3.3M in sales from five insiders. GEO's SVP sold $371K, TSEM's director sold $49K, TGTX's director sold $275K, and GCT's director sold $158K.
1 min read
